{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:05:50Z","timestamp":1790334350323,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2168,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.exphem.2016.04.005","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T02:47:13Z","timestamp":1461984433000},"page":"567-573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for\u00a0Blood\u00a0and Marrow Transplantation"],"prefix":"10.1016","volume":"44","author":[{"given":"Michael","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2016.04.005_bib1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/ijerph9072444","article-title":"Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor","volume":"9","author":"Ezoe","year":"2012","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.exphem.2016.04.005_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/leu.2015.258","article-title":"Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation","volume":"30","author":"Radivoyevitch","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.04.005_bib3","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2014-04-522136","article-title":"Recent developments in myelodysplastic syndromes","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib4","unstructured":"SEER stat fact sheets: acute myeloid leukemia (AML). Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. [Accessed Oct 26, 2015]."},{"key":"10.1016\/j.exphem.2016.04.005_bib5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2016.04.005_bib7","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.exphem.2016.04.005_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00043426-200112000-00008","article-title":"Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy","volume":"23","author":"Tzortzatou-Stathopoulou","year":"2001","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib9","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib10","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib11","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib12","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2016.04.005_bib13","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.04.005_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.11960","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"93","author":"Mohty","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.04.005_bib17","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2008-10-184093","article-title":"Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation","volume":"113","author":"Bachanova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2009.102","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study","volume":"23","author":"Cho","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.04.005_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2016.106","article-title":"The devil is in the T-cells: Relapsing after haploidentical hematopoietic cell transplantation","author":"Byrne","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib20","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.04.005_bib21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bmt.2012.236","article-title":"Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT","volume":"48","author":"Martino","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib24","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib25","doi-asserted-by":"crossref","unstructured":"Scott BL, Pasquini MC, Logan B, et\u00a0al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Paper presented at: American Society of Hematology 57th Annual Meeting and Exposition; December 5\u20138, 2015; Orlando, FL.","DOI":"10.1182\/blood.V126.23.LBA-8.LBA-8"},{"key":"10.1016\/j.exphem.2016.04.005_bib26","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/bmt.2012.4","article-title":"Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity","volume":"47","author":"Shimoni","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib28","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1987.tb06160.x","article-title":"Risk factors for acute graft-versus-host disease","volume":"67","author":"Gale","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2016.04.005_bib29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/00007890-199106000-00010","article-title":"Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation","volume":"51","author":"Weisdorf","year":"1991","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2016.04.005_bib30","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V80.7.1838.1838","article-title":"Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate","volume":"80","author":"Nash","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib31","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.V94.4.1465","article-title":"Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation","volume":"94","author":"Przepiorka","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib32","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2008.17.6545","article-title":"Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia","volume":"26","author":"Hahn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib33","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bmt.2012.187","article-title":"Risk and prognostic factors for acute GVHD based on NIH consensus criteria","volume":"48","author":"Lee","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib35","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1053\/bbmt.2002.v8.abbmt080674","article-title":"Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Remberger","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.bmt.1701423","article-title":"Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis","volume":"22","author":"Carlens","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib37","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib38","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood.V75.12.2459.2459","article-title":"Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation","volume":"75","author":"Atkinson","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib39","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1200\/JCO.2012.45.0247","article-title":"Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation","volume":"31","author":"Storb","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib40","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3324\/haematol.2011.049841","article-title":"The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality","volume":"96","author":"Pidala","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.04.005_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1703808","article-title":"Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival","volume":"31","author":"Gustafsson Jernberg","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib43","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/bmt.2011.162","article-title":"Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation","volume":"47","author":"Svahn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1634\/theoncologist.2013-0406","article-title":"Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens","volume":"19","author":"Khera","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.exphem.2016.04.005_bib45","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib46","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","article-title":"Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study","volume":"108","author":"Fraser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib47","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2010-07-295766","article-title":"Significant differences in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated dysgammaglobulinemia","volume":"117","author":"Kuzmina","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood.V70.3.779.779","article-title":"Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation","volume":"70","author":"Aucouturier","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib49","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1182\/blood.V95.12.3683","article-title":"Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants","volume":"95","author":"Kulkarni","year":"2000","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2016.04.005_bib50","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/sj.bmt.1704848","article-title":"Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future","volume":"35","author":"Fry","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib51","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2010-03-276576","article-title":"Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management","volume":"116","author":"Griffith","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib52","first-page":"395","article-title":"Bone density loss during treatment of chronic GVHD","volume":"17","author":"Stern","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib53","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1210\/jc.2006-2870","article-title":"Bone loss and its management in long-term survivors from allogeneic stem cell transplantation","volume":"92","author":"Tauchmanov\u00e0","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.exphem.2016.04.005_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3324\/haematol.2015.135699","article-title":"Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT","volume":"101","author":"Savani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.04.005_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2011.10.008","article-title":"Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines","volume":"49","author":"Abboud","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2016.04.005_bib56","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2002-07-2231","article-title":"Nonmalignant late effects after allogeneic stem cell transplantation","volume":"101","author":"Soci\u00e9","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib57","first-page":"1163","article-title":"Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation","volume":"88","author":"Spinelli","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2016.04.005_bib58","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1182\/blood-2013-05-499806","article-title":"Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation","volume":"122","author":"Wong","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib59","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/bmt.2013.17","article-title":"Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight\u2013new perspectives?","volume":"48","author":"Ditschkowski","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2012.299","article-title":"Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced","volume":"27","author":"Shimoni","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2016.04.005_bib61","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.04.005_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2001.19.2.464","article-title":"Solid cancers after bone marrow transplantation","volume":"19","author":"Bhatia","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib63","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.04.005_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2012.01811.x","volume":"89","author":"Nagler","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2016.04.005_bib66","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1056\/NEJMoa011826","article-title":"Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation","volume":"345","author":"Petersdorf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.04.005_bib67","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/01.TP.0000129809.09718.7E","article-title":"A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation","volume":"78","author":"Le Blanc","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2016.04.005_bib68","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM198509263131301","article-title":"Marrow transplantation from related donors other than HLA-identical siblings","volume":"313","author":"Beatty","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2016.04.005_bib69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bbmt.2007.01.084","article-title":"Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation","volume":"13","author":"Remberger","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbmt.2007.10.025","article-title":"Graft failure after allogeneic hematopoietic cell transplantation","volume":"14","author":"Mattsson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib71","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.V78.8.2120.2120","article-title":"T-cell depletion of HLA-identical transplants in leukemia","volume":"78","author":"Marmont","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib72","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2012.02.013","volume":"18","author":"Nagler","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib73","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2014.57.2446","article-title":"Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation","volume":"33","author":"Eapen","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib74","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","article-title":"Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation","volume":"11","author":"Wong","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib75","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2016.04.005_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.bmt.1705207","article-title":"Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up","volume":"37","author":"Oyekunle","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib77","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V89.11.4226","article-title":"Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose","volume":"89","author":"Sierra","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2016.04.005_bib78","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.bmt.1702690","article-title":"Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle (SFGM)","volume":"26","author":"Michallet","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2016.04.005_bib79","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16300777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16300777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:15:53Z","timestamp":1654924553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16300777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0301472X16300777"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2016.04.005","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for\u00a0Blood\u00a0and Marrow Transplantation","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2016.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH - International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}]}}